Jazz Pharmaceuticals Completes $820M Actio Biosciences Acquisition, Adding First-in-Class KCNT1 Epilepsy Candidate ABS-1230

Jazz Pharmaceuticals查看公司主页 plc has completed its acquisition of privately held Actio Biosciences (搜索)搜索该词条, Inc. for $820 million upfront, adding the clinical-stage epilepsy candidate ABS-1230查看药品详情 to its rare disease pipeline. The transaction closed on September 15, 2026, and Actio is now a wholly owned subsidiary of Jazz.

The acquisition was effected through the merger of Knight Acquisition Corp., an indirect wholly owned subsidiary of Jazz, with and into Actio. Actio continues as the surviving corporation and an indirect wholly owned subsidiary of Jazz.

A Precision Therapy Targeting KCNT1

ABS-1230查看药品详情 is an orally available small-molecule inhibitor designed to selectively target KCNT1 (搜索)搜索该靶点, a potassium channel associated with KCNT1-related epilepsy (搜索)搜索该疾病. Jazz describes the candidate as a potent and selective KCNT1 inhibitor with the potential to be a first-in-class precision therapy, offering patients the convenience of oral administration.

In preclinical studies, ABS-1230查看药品详情 inhibited KCNT1 (搜索)搜索该靶点 across all evaluable pathogenic mutations, suggesting potential activity across the full population of patients with KCNT1-related epilepsy (搜索)搜索该疾病. In an early clinical proof-of-concept trial, children with KCNT1-related epilepsy who received ABS-1230 experienced meaningful seizure reductions, findings that Jazz said support further clinical development of the therapy.

"ABS-1230查看药品详情 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy (搜索)搜索该疾病," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals查看公司主页. "By completing the acquisition of Actio Biosciences (搜索)搜索该词条, we are combining their cutting-edge precision biology with Jazz's proven global development capabilities. We look forward to partnering with advocates, clinicians, and regulators to move with urgency, rapidly advance this vital treatment, and further diversify our rare disease pipeline."

Regulatory Designations and Development Path

ABS-1230查看药品详情 has received Fast Track, Rare Pediatric Disease and Orphan Drug Product designations from the U.S. Food and Drug Administration. The program has also been accepted into the FDA's Rare Disease Evidence Principles process.

Jazz said it plans to advance ABS-1230查看药品详情 through clinical development for KCNT1-related epilepsy (搜索)搜索该疾病 while working with patients, clinicians and regulators to accelerate development of the potential precision therapy. The company framed the acquisition as strengthening its epilepsy pipeline and reinforcing its commitment to advancing treatment options in rare disease, where patients often have limited or no therapeutic options.

Transaction Structure and Spun-Out Programs

As part of the transaction, Actio spun out a new privately held entity to which certain non-ABS-1230查看药品详情 programs were transferred. The new, independent private company is funded by existing investors, with Jazz receiving a minority stake and certain related rights.

Jazz, headquartered in Dublin, Ireland, is a global biopharmaceutical company with a portfolio that includes therapies addressing epilepsies, cancers and sleep disorders. The company said the acquisition combines Actio's precision biology capabilities with its global development expertise and further diversifies its rare disease pipeline.

Jazz noted in its announcement that the transaction and the development of ABS-1230查看药品详情 remain subject to risks and uncertainties, including the difficulty of predicting the timing or outcome of regulatory approvals, the possibility that anticipated acquisition benefits will not be realized, and the uncertainty of clinical success, including risks related to failure or delays in initiating or completing clinical trials.